Novel mechanistic and clinical implications concerning the safety of statin discontinuation

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Pharmacological Reports

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1734-1140(11)70602-8PMID 22001974
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes

  2012cited by this paper
• Clinical aspects of coenzyme Q10: an update.

  2010cited by this paper
• Neuromuscular symptoms and elevated creatine kinase after statin withdrawal.

  2010cited by this paper
• Effects of statins on nitric oxide/cGMP signaling in human umbilical vein endothelial cells

  2010cited by this paper
• When statin therapy stops: implications for the patient

  2009cited by this paper
• Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase.

  2009cited by this paper
• Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal.

  2009cited by this paper
• C-reactive protein level following treatment and withdrawal of lovastatin in diabetic nephropathy.

  2009cited by this paper
• Withdrawal of Statins and Risk of Subarachnoid Hemorrhage

  2009cited by this paper
• Statin discontinuation: an underestimated risk?

  2008cited by this paper
• Discontinuation of statin therapy following an acute myocardial infarction: a population-based study.

  2008cited by this paper
• Atorvastatin-induced changes in plasma coenzyme q10 and brain natriuretic peptide in patients with coronary artery disease.

  2008cited by this paper
• Effects of Initiation and Acute Withdrawal of Statins on the Neurovascular Coupling Mechanism in Healthy, Normocholesterolemic Humans

  2007cited by this paper
• Statin treatment withdrawal in ischemic stroke

  2007cited by this paper
• Dyslipidemia: Factors Related to Adherence to Statin Therapy

  2007cited by this paper
• Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice.

  2007cited by this paper
• Statins and the endothelium.

  2007cited by this paper
• Do we need to assess the effect of treatment withdrawal? The paradigm of life-long prevention.

  2007cited by this paper
• Upregulation of Angiotensin II-AT1 Receptors During Statin Withdrawal in Vascular Smooth Muscle Cells

  2007influential reference
• Discontinuation of Statin Therapy and Clinical Outcome After Ischemic Stroke

  2007cited by this paper
• Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients

  2006cited by this paper
• Re-elevation of high-sensitivity C-reactive protein but not the von Willebrand Factor after withdrawing atorvastatin therapy in patients with unstable angina undergoing coronary artery stenting.

  2006cited by this paper
• Discontinuation of Statin Treatment in Stroke Patients

  2006cited by this paper
• Effect of atorvastatin withdrawal on circulating coenzyme Q10 concentration in patients with hypercholesterolemia

  2006cited by this paper
• High-dose atorvastatin after stroke or transient ischemic attack.

  2006cited by this paper
• Statin Withdrawal: Clinical Implications and Molecular Mechanisms

  2006cited by this paper
• Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal.

  2006cited by this paper
• A carbon monoxide-releasing molecule (CORM-3) attenuates lipopolysaccharide- and interferon-gamma-induced inflammation in microglia.

  2006cited by this paper
• Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.

  2006cited by this paper
• High-dose atorvastatin after stroke or transient ischemic attack.

  2006cited by this paper
• Correlation Between Inflammation and Oxidative Stress in Normocholesterolemic Coronary Artery Disease Patients ‘on’ and ‘off’ Atorvastatin for Short Time Intervals

  2006cited by this paper
• Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention.

  2005cited by this paper
• Therapeutic roles of peroxisome proliferator-activated receptor agonists.

  2005cited by this paper
• Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture.

  2005cited by this paper
• High‐dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial

  2005cited by this paper
• Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells.

  2005cited by this paper
• Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation.

  2005cited by this paper
• Stroke Prevention by Aggressive Reduction in Cholesterol Levels

  2004cited by this paper
• Rho and Rac take center stage.

  2004cited by this paper
• C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.

  2004influential reference
• Antioxidant effects of statins.

  2004cited by this paper
• Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction.

  2004cited by this paper
• Stopping statins.

  2004cited by this paper
• Differential modulation of caveolin-1 expression in cells of the vasculature by statins.

  2004cited by this paper
• The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging.

  2004cited by this paper
• Statin-Induced Cholesterol Lowering and Plaque Regression After 6 Months of Magnetic Resonance Imaging–Monitored Therapy

  2004cited by this paper
• Lymphocyte function-associated antigen-1 blockade by statins: molecular basis and biological relevance.

  2003cited by this paper
• New Markers of Inflammation and Endothelial Cell Activation: Part I

  2003cited by this paper
• Withdrawal of Cerivastatin Induces Monocyte Chemoattractant Protein 1 and Tissue Factor Expression in Cultured Vascular Smooth Muscle Cells

  2003cited by this paper
• Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch.

  2003cited by this paper
• Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome.

  2003cited by this paper
• Platelet hyperactivity after statin treatment discontinuation

  2003cited by this paper
• Statin inhibits interferon-γ-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells

  2002cited by this paper
• Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro.

  2002cited by this paper
• Withdrawal of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Elicits Oxidative Stress and Induces Endothelial Dysfunction in Mice

  2002cited by this paper
• Rho GTPase signalling pathways in the morphological changes associated with apoptosis

  2002cited by this paper
• Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes

  2002cited by this paper
• Ras family genes: An interesting link between cell cycle and cancer

  2002cited by this paper
• Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes.

  2002cited by this paper
• Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes

  2002cited by this paper
• Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.

  2001cited by this paper
• An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro

  2001influential reference
• Role for Tissue Factor Pathway in Murine Model of Vascular Remodeling

  2001cited by this paper
• Statins Alter Smooth Muscle Cell Accumulation and Collagen Content in Established Atheroma of Watanabe Heritable Hyperlipidemic Rabbits

  2001cited by this paper
• ERRATA

  2001cited by this paper
• Expression and Function of PPARg in Rat and Human Vascular Smooth Muscle Cells

  2000cited by this paper
• Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice

  2000cited by this paper
• Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

  2000cited by this paper
• Expression and Function of PPARγ in Rat and Human Vascular Smooth Muscle Cells

  2000cited by this paper
• The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.

  2000cited by this paper
• Suppression of Endothelial Nitric Oxide Production After Withdrawal of Statin Treatment Is Mediated by Negative Feedback Regulation of Rho GTPase Gene Transcription

  2000influential reference
• Pravastatin: An Antithrombotic Effect Independent of the Cholesterol-lowering Effect

  2000cited by this paper
• Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.

  2000cited by this paper
• 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Attenuate Vascular Smooth Muscle Proliferation by Preventing Rho GTPase-induced Down-regulation of p27 Kip1 *

  1999cited by this paper
• Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.

  1999cited by this paper
• Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor.

  1999cited by this paper
• Inducible nitric oxide synthase and vascular injury.

  1999cited by this paper
• NO: the primary EDRF.

  1999cited by this paper
• Nitric oxide and the proliferation of vascular smooth muscle cells.

  1999cited by this paper
• Rho GTPases and the actin cytoskeleton.

  1998cited by this paper
• Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase*

  1998cited by this paper
• Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms.

  1998cited by this paper
• Increased thrombotic vascular events after change of statin.

  1998cited by this paper
• Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

  1998cited by this paper
• Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.

  1998cited by this paper
• Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.

  1997cited by this paper
• Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.

  1997cited by this paper
• Rho GTPases and signaling networks.

  1997cited by this paper
• P-selectin and vascular cell adhesion molecule-1 are focally expressed in aortas of hypercholesterolemic rabbits before intimal accumulation of macrophages and T lymphocytes.

  1997cited by this paper
• Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression.

  1996cited by this paper
• Impaired mitochondrial function in idiopathic dilated cardiomyopathy: biochemical and molecular analysis.

  1995cited by this paper
• Molecular bases of the acute coronary syndromes.

  1995cited by this paper
• Leucocyte-endothelial interactions and regulation of leucocyte migration.

  1994cited by this paper
• An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium.

  1993cited by this paper
• The expression of the adhesion molecules ICAM‐1, VCAM‐1, PECAM, and E‐selectin in human atherosclerosis

  1993cited by this paper
• Molecular Biology of the Renin‐Angiotensin System

  1993cited by this paper
• [Molecular biology in renin angiotensin system].

  1992cited by this paper
• Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

  1990cited by this paper
• Inducible Endothelial Functions in Inflammation and Coagulation

  1987cited by this paper

• Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo.

  2026cites this paper
• Deprescribing statins, considerations for informed decision making.

  2023cites this paper
• A systematic review and meta-analysis on impact of suboptimal use of antidepressants, bisphosphonates, and statins on healthcare resource utilisation and healthcare cost

  2022cites this paper
• Atorvastatin alleviates left ventricular remodeling in isoproterenol-induced chronic heart failure in rats by regulating the RhoA/Rho kinase signaling pathway

  2020cites this paper
• Gaps in Dyslipidemia Care Among Working‐Aged Individuals With Employer‐Sponsored Health Care

  2020cites this paper
• Predictors of first-year statin medication discontinuation: A cohort study

  2016cites this paper
• Statin Adherence, Utilisation, and Prescribing Patterns. Improving effectiveness of treatment

  2016cites this paper
• Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia

  2015cites this paper
• Patients who discontinued statin treatment: a protocol for cohort study using primary care data

  2015cites this paper
• Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patients.

  2015cites this paper
• Adverse neurologic effects of medications commonly used in the intensive care unit.

  2014cites this paper
• Similia similibus curentur: o princípio de cura homeopático fundamentado na farmacologia moderna

  2013cites this paper
• Discontinuation of Statin Treatment in Relation to Chronic Diseases and Laboratory Findings

  2013cites this paper
• Anti-atherosclerotic mechanisms of statin therapy.

  2013cites this paper
• Statins as treatments of dyslipidemia and atherosclerosis Babelova

  2013cites this paper
• Wound healing signals mediated by Rho/ROCK activation in response to radiotherapy and consequences fot treatmeny of late damage within normal tissues

  2012cites this paper
• Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model.

  2012cites this paper